Psychedelic Drugs: Global Market Outlook

Psychedelic Drugs: Global Market Outlook

Report Scope:

This report includes sales forecasts and trends in the market for psychedelic drugs through 2027. It discusses leading companies in the market, product segments, supporting technologies, market dynamics, competitive intelligence and regional trends. It also discusses market the competitive scenarios that will form the base data for qualitative analysis and market estimates.

In this report, the global market for psychedelic drugs is segmented into four geographic regions: North America, Europe, Asia and RoW (South America, the Middle East and Africa).

Report Includes:

12 data tables and 9 additional tables

A brief general outlook of the global market for psychedelic drugs within the biopharmaceutical industry

Analyses of the global market trends, with historic sales data for 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027

Highlights of the current and future market potential of psychedelic drugs, along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement and market dynamics

Estimation of the actual market size and revenue forecast for global psychedelic drugs market in USD million values, and corresponding market share analysis based on drug type, application, and region

Information on stringent regulatory policies and government guidelines to impede the adoption rate of the psychedelic drugs

Review of key marketed and pipelined products indicated for different therapeutic applications, clinical trials, and penetration of technologies and research initiatives within the ecosystem

Company profiles of major players within the industry, including Pfizer Inc., Celon Pharma, Cybin Corp., Jazz Pharmaceuticals Inc., and PharmaTher Holdings Ltd.

Companies Mentioned

Celon Pharma S.a.
Cybin Corp.
Hikma Pharmaceuticals Plc.
JAZZ PHARMACEUTICALS INC.
Mind Medicine Inc.
PFIZER INC.
PharmaTher Holdings Ltd.
Revive Therapeutics Ltd.